Celldex reports quality of life gains in urticaria studies

March 27, 2026 10:30 AM

Celldex Therapeutics Inc. (NASDAQ: CLDX) presented data from Phase 2 clinical trials showing that its drug candidate barzolvolimab improved quality ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found